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Abstract
Background: Endothelial dysfunction has been implicated in the pathogenesis of diverse pathologies ranging from vascular
and immune diseases to cancer. TNF-a is one of the mediators of endothelial dysfunction through the activation of
transcription factors, including NF-kB. While HUVEC (macrovascular cells) have been largely used in the past, here, we
documented an NF-kB gene signature in TNFa-stimulated microvascular endothelial cells HMEC often used in tumor
angiogenesis studies.
Methodology/Principal Findings: We measured mRNA expression of 55 NF-kB related genes using quantitative RT-PCR in
HUVEC and HMEC. Our study identified twenty genes markedly up-regulated in response to TNFa, including adhesion
molecules, cytokines, chemokines, and apoptosis regulators, some of them being identified as TNF-a-inducible genes for
the first time in endothelial cells (two apoptosis regulators, TNFAIP3 and TNFRSF10B/Trail R2 (DR5), the chemokines GM-
CSF/CSF2 and MCF/CSF1, and CD40 and TNF-a itself, as well as NF-kB components (RELB, NFKB1or 50/p105 and NFKB2 or
p52/p100). For eight genes, the fold induction was much higher in HMEC, as compared to HUVEC. Most importantly, our
study described for the first time a connection between NF-kB activation and the induction of most, if not all, of these genes
in HMEC as evaluated by pharmacological inhibition and RelA expression knock-down by RNA interference. Moreover,
since TNF-a is highly expressed in tumors, we further applied the NF-kB gene signature documented in TNFa-stimulated
endothelial cells to human breast tumors. We found a significant positive correlation between TNF and the majority (85 %)
of the identified endothelial TNF-induced genes in a well-defined series of 96 (48 ERa positive and 48 ERa negative) breast
tumors.
Conclusion/Significance: Taken together these data suggest the potential use of this NF-kB gene signature in analyzing the
role of TNF-a in the endothelial dysfunction, as well as in breast tumors independently of the presence of ERa.
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Introduction
Tumor necrosis factor (TNF-a) is a potent multi-functional
cytokine produced by various cells, including neutrophils, activated
macrophages, T and natural killer cells, and fibroblasts, in response
to inflammation, infection, tissue injury and other environmental
challenges. TNF-a elicits a large number of biological activities
including the control of cell proliferation, differentiation and
apoptosis, and is an important mediator of inflammation and
immunity [1]. Considerable progress has been made in understand-
ing the molecular mechanisms that mediate TNF-a-induced cellular
responses. TNF-a binds to membrane receptors, TNFR1 (or TNF-
Rp55) and TNFR2 (or TNF-Rp75), which initiate signalling
pathway leading to gene induction via activation of transcription
factors [2–3]. TNFR1 is ubiquitously expressed, while TNFR2
expression is restricted to endothelial and hematopoietic cells [4].
Through complex signaling cascades and networks, signal transduc-
ers lead to the activation of transcription factors (NF-kB, AP-1 and
SP1) [2] and their binding to the promoters of specific genes.
The transcription factor NF-kB is a key inducible transcription
factor which regulates numerous genes controlling inflammation,
immune response, cell growth, tissue differentiation and apoptosis
[5–7]. NF-kB-activating signals emanate from cell surface
receptors for inflammatory cytokines (such as TNF-a, IL-1, or
LPS), growth factors, lymphokines, reactive oxygen intermediates,
viral infection, and B or T cell activation [5]. NF-kB factors are
homo- and heterodimeric transcription factors that belong to the
Rel family; this family is composed of five homologous subunits in
mammals: NF-kB1 (p50 and its precursor p105), NF-kB2 (p52 and
its precursor p100), RelA/p65, RelB and c-Rel. Biological activity
mediated by NF-kB occurs through two main signalling pathways,
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specifically induced in response to TNF-a, whereas the latter is
induced by other specific stimuli [6–8]. In the classical pathway,
the inactive NF-kB complexes are sequestered in the cytoplasm
through interaction with specific inhibitors, the IkB proteins
(IkBa,I kBb, especially). Following stimulation by TNF-a,
activation of the IkB kinase (IKK) complex leads to the
degradation of IkB proteins and subsequent release of mainly
RelA/p50 dimers, which subsequently translocate into the nucleus
where they bind to specific sites within the promoter of specific
target genes. Based on studies on fibroblasts and B cell maturation,
biological activity mediated by NF-kB may also occur through
alternative pathway involving the activation of IKKa (IKK1) and
the activation of RelB/p52 and RelB/p50 dimers [9–11].
Endothelial dysfunction has been implicated in the pathogenesis
of diverse pathologic processes ranging from vascular diseases to
cancer and metastasis. TNF-a mediated endothelial changes are
relevant to acute inflammation, a highly complex biologic cascade-
involving cytokines (such as IL6), chemokines IL-8 and MCP-1,
and the induction of adhesion molecules (VCAM, ICAM and E
selectin) [12–17] that recruit and activate granulocytes, mono-
cytes/macrophages, and lymphocytes at the damaged tissue site.
NF-kB often plays a major role in these pathways [17–18]. The
diversity of the vascular bed is crucially determined by the type of
endothelial cells which can be divided into microvascular and
macrovascular endothelial cells. Although many reports have
addressed the biological responses of human macrovascular
endothelial cells (HUVEC) to TNF-a[14–15,19], the detailed
dissection of the coordinated expression of TNF-a-inducible genes
via NF-kB has not been performed in human microvascular
endothelial cells (HMEC).
In this study, we have determined the expression profile of 55
selected key genes in TNF-a-stimulated HMEC, that are all
known as being regulated by NF-kB in other cell types in
response to various stress responses [20-21]. HMEC were
c h o s e n ,i na d d i t i o nt oH U V E Cw h i c hh a v eb e e nl a r g e l yu s e d
in the past, because they originate from the microcirculation,
their varying thresholds to cytokines have been previously
described and they are often used in tumor angiogenesis studies.
Using real-time reverse transcription (RT)-PCR, we demonstrat-
ed that 36.4 % (20/55) genes are markedly up-regulated
(.5-fold) by TNF-a in a dose- and time-dependent pathway in
HMEC. Using two NF-kB inhibitors and a direct approach of
RelA expression knock-down by RNAi, we demonstrated that
t h eg e n es i g n a t u r eo b s e r v e di nT N F - a stimulated HMEC is NF-
kB-dependent. Intracellular signalling pathways triggered by
TNF-a leading to numerous tumors have been partially
delineated, with NF-kB playing an important role especially in
breast cancer cells [20–25]. However, the stroma of a solid
tumor is vital for its survival, and key components in this respect
are the blood vessels. We further demonstrated that tumors
producing high amount of TNF-a could have similar dysregu-
lated NF-kB endothelial pathways.
Materials and Methods
Cell culture experiments
Human microvascular endothelial cells (HMEC) from derma
(ATCC, Molsheim, France) were cultured in MCDB 131 medium
(Gibco) supplemented with 10 % FBS, hydrocortisone (1 mg/ml;
Sigma), epidermal growth factor (0.5%; Sigma), glutamine 2 mM,
100 U/ml penicillin and 100 mg/ml streptomycin. Human
umbilical vein endothelial cells (HUVEC) were isolated with
Collagenase I [26]. Cells were cultured on 0.2% gelatin-coated
dishes in Medium 199 (M199) supplemented with 20% FBS,
2 mM glutamine, 100 mg/ml streptomycin, 15 mM of HEPES,
and 0.4% ECGS (Promocell, Heidelberg, Deutschland). Second
passaged cells and mix of three cords were used for all
experiments. Cell cultures were incubated at 37uC in a humid
atmosphere of 5 % CO2-95 % air. Once cells had grown to 80 %
confluence, TNF-a (R&D Systems; Minneapolis, MN) was added
into the medium at the indicated concentrations (1–80 ng/ml).
The NF-kB inhibitors, Bay 11–7082 (10 mM; Calbiochem) [27]
and the IkKb kinase (IKK-2) inhibitor V (3,5-bis-trifluoromethyl-
phenyl)5-cloro-2-hydroxybenzamide, Calbiochem) [28] were add-
ed in some experiences.
Table 1. Characteristics of the 48 ERa-positive and the 48 ERa-negative breast tumors.
ERa-positive breast tumors ERa-negative breast tumors
Number of patients Number of relapses (%) p-value
a
Number of
patients
Number of
relapses (%) p-value
a
Age
#70 27 14 (51.9) NS 40 17 (42.5) NS
.70 21 10 (47.6) (0.39) 8 2 (25.0) (0.51)
SBR histological grade
b
I + II 38 16 (42.1) NS 6 5 (83.3) NS
III 10 8 (80.0) (0.13) 39 14 (35.9) (0.058)
Lymph node status
#3 32 13 (40.6) 0.023 41 16 (39.0) NS
.3 16 11 (68.7) 6 3 (50.0) (0.96)
Macroscopic tumor size
#30 mm 32 14 (43.8) NS 27 13 (48.1) NS
.30 mm 16 10 (62.5) (0.076) 20 6 (30.0) (0.15)
aLog-rank test. NS: not significant.
bScarff Bloom Richardson classification.
doi:10.1371/journal.pone.0021589.t001
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Gene symbols
Protein
symbols Gene name
Chromosome
location
Genbank accession
number
NFKB genes (n=10)
NFKB1 p50, p105 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 4q24 NM_003998
NFKB2 p52, p100 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 10q24 NM_002502
REL C-Rel v-rel reticuloendotheliosis viral oncogene homolog 2p13-p12 NM_002908
RELA p65, NFKB3 v-rel reticuloendotheliosis viral oncogene homolog A (p65) 11q13 NM_021975
RELB I-REL v-rel reticuloendotheliosis viral oncogene homolog B 19q13.32 NM_006509
CHUK IkKa Conserved helix-loop-helix ubiquitous kinase 10q24-q25 NM_001278
IKBKB IkKb Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 8p11.2 NM_001556
IKBKG IkKc, Nemo Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma Xq28 NM_003639
NFKBIA IkBa Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 14q13 NM_020529
NFKBIB IkBb Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta 19q13.1 NM_002503
Apoptosis (n=12)
BCL2A1 BFL1/A1 Baculoviral IAP repeat-containing 2 15q24.3 NM_004049
GADD45B Growth arrest and DNA-damage-inducible, beta 19p13.3 NM_015675
TNFRSF10B TRAILR2 Tumor necrosis factor receptor superfamily, member 10b 8p22-p21 NM_003842
FASLG TNFSF6 Fas ligand (TNF superfamily, member 6) 1q23 NM_000639
BIRC4 XIAP Baculoviral IAP repeat-containing 4 Xq25 NM_001167
TNFAIP3 A20 Tumor necrosis factor, alpha-induced protein 3 6q23 NM_006290
TRAF2 TNF receptor-associated factor 2 9q34 NM_021138
IER3S Immediate early response 3, large transcript 6p21.3 NM_003897
IER3L Immediate early response 3, short transcript 6p21.3 NM_052815
BIRC2 c-IAP1 Baculoviral IAP repeat-containing 2 11q22 NM_001166
MCL1S Myeloid cell leukemia sequence 1 (BCL2-related), short transcript 1q21 NM_182763
MCL1L Myeloid cell leukemia sequence 1 (BCL2-related), large transcript 1q21 NM_021960
Immune response (n=12)
IL1A Interleukin 1, alpha 2q14 NM_000575
IL1B Interleukin 1, beta 2q14 NM_000576
IL6 Interleukin 6 (interferon, beta 2) 7p21 NM_000600
IL12B Interleukin 12B (natural killer cell stimulatory factor 2) 5q31.1-q33.1 NM_002187
CCL2 MCP-1 Chemokine (C-C motif) ligand 2 17q11.2-q21.1 NM_002982
TNFRSF11A RANK Tumor necrosis factor receptor superfamily, member 11a, activator of NFKB 18q22.1 NM_003839
TNFSF11 RANKL Tumor necrosis factor (ligand) superfamily, member 11 13q14 NM_003701
TNF Tumor necrosis factor (TNF superfamily, member 2) 6p21.3 NM_000594
TNFRSF1A TNFR1 Tumor necrosis factor receptor superfamily, member 1A 12p13.2 NM_001065
TNFRSF1B TNFR2 Tumor necrosis factor receptor superfamily, member 1B 1p36.3-p36.2 NM_001066
CD40 CD40 antigen (TNF receptor superfamily member 5) 20q12-q13.1 NM_001250
CD40LG CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) Xq26 NM_000074
Cell Proliferation (n=7)
CSF1 MCSF Colony stimulating factor 1 (macrophage) 1p21-p13 NM_000757
CSF1R Colony stimulating factor 1 receptor, v-fms oncogene homolog 5q33-q35 NM_005211
CSF2 GMCSF Colony stimulating factor 2 (granulocyte-macrophage) 5q31.1 NM_000758
CCND1 Cyclin D1 (PRAD1 : parathyroid adenomatosis 1) 11q13 NM_053056
CCND2 Cyclin D2 12p13 NM_001759
CCND3 Cyclin D3 6p21.3 NM_001760
CCNG1 Cyclin G1 5q32-q34 NM_004060
Tumor progression (n=9)
MMP9 Matrix metalloproteinase 9 (gelatinase B, 92kDa type IV collagenase) 20q11.2-q13.1 NM_004994
MMP11 Matrix metalloproteinase 11 (stromelysin 3) 22q11.23 NM_005931
PLAU UPA Plasminogen activator, urokinase 10q24 NM_002658
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Subconfluent HMEC were transfected in OPTI-MEM medium
(Gibco) with Fugene (4 mg per P30 flask; Roche) containing a
construct of firefly luciferase ligated to a NF-kB -sensitive
promoter of the gene [29]. Twenty hours later, cells were
incubated with Bay 11–7082 (10 mM) and stimulated with TNF-
a (40 ng/ml) for 4 h in the presence of the inhibitor, before they
were harvested; pellets were analyzed for luciferase activity.
Results are given as firefly luciferase activity as compared to TNF
stimulation
Transient of siRNA. TNFR1 and TNFR2 were silenced
using a specific siRNA mix containing three different siRNAs
provided by Santa Cruz Biotechnology, as previously described
[30]. As a control, siRNA with a nonsense sequence was usedg.
Briefly, 10 mM of siRNA was added to the transfection reagent
(Oligofectamine, InVitrogen; 1.25 mg) and subsequently
transferred to culture plates P100 flask with 4610
5/flask
HMEC. Then, 24 hours after transfection, cells were stimulated
with TNF-a for 4 h and the specific experiment was performed.
Plasmid constructs. pTrip-shRNA RelA was generated by
subcloning an oligonucleotide designed to target RelA under
control of the H1 promoter into pTRIP-DU3-MND-GFP
lentiviral vector [31]. pTRIP-shRNA control was generated
following the same approach using a scrambled control
oligonucleotide. Sequences are available upon request.
Lentiviral infection. Production of infectious recombinant
lentiviruses was performed by transient transfection of 293T cells,
as previously described [31]. For infections, 10
5 cells in 35-mm
dishes were transduced with 5000 ng/ml of p24 (HIV-1 capsid
protein). 48 h later, cells were washed and fresh medium was
added. The culture was then continued as described above.
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared and analyzed for DNA binding
activity using the HIV-LTR tandem kB oligonucleotide as kB
probe [32]. For supershift assays, nuclear extracts were incubated
with specific antibodies for 30 min on ice before incubation with
the labeled probe. Anti-RelA, RelB, cRel, and p105/p50
supershifting antibodies were purchased from Santa Cruz
Biotechnology.
Gene symbols
Protein
symbols Gene name
Chromosome
location
Genbank accession
number
CXCR4 Chemokine (C-X-C motif) receptor 4 2q21 NM_003467
CXCL12 SDF1 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 10q11.1 NM_000609
ICAM1 Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor 19p13.3-p13.2 NM_000201
VCAM1 Vascular cell adhesion molecule 1 1p32-p31 NM_001078
SELE ELAM1 Selectin E (endothelial adhesion molecule 1) 1q22-q25 NM_000450
TNC HXB Tenascin C (hexabrachion) 9q33 NM_002160
Angiogenesis (n=4)
IL8 Interleukin 8 4q13-q21 NM_000584
CXCL1 GRO1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 4q21 NM_001511
VEGF VEGFA Vascular endothelial growth factor 6p12 NM_003376
PTGS2 COX2 Prostaglandin-endoperoxide synthetase 2 1q25.2-q25.3 NM_000963
Divers (n=1)
EGR1 Early growth response 1 5q31.1 NM_001964
doi:10.1371/journal.pone.0021589.t002
Table 2. Cont.
Table 3. Effect of tumor necrosis factor (TNF-a treatment on
selected NF-kB gene expression in HMEC cells.
Gene Mean
a +/2 SEM
TNF 1156+/2 336
SELE 1022+/2 102
VCAM 896+/2 246
CSF2/GMCSF 762+/2 89
IL8 726+/2 91
ICAM 357+/2 103
CCL2/MCP1 75+/2 8,2
CXCL1/GRO1 71+/2 8,3
RELB 63+/2 11,4
TNFAIP3/A20 49+/2 7,5
IL1A 31+/2 0,7
IL1B 26+/2 0,5
BCL2A1 21+/2 2,3
NFKB2 20+/2 1,9
NFKBIA 18+/2 0,8
CSF1 14+/2 1,1
NFKB1 8,7+/2 0,4
CD40 5,3+/2 1,1
IL6 5,3+/2 0,6
TNFRSF10B 5,1+/2 0,1
MKI67 0,9+/2 0,1
ESR1/ERa NQ
b
aRatio of the mRNA content in stimulated cells for 4 hours by TNF-a to the
mRNA content in the unstimulated cells was calculated. This time was chosen
from preliminary kinetic analysis on gene candidates (such as E-selectin and
IL-8) (see also Table 4). Values shown are calculated from three independent
experiments, each experiment in duplicate.
bNQ, not quantifiable: very low levels of target gene mRNA that were only
detectable, but not quantifiable, by means of the real-time quantitative RT-PCR
assay (Ct values .35).
doi:10.1371/journal.pone.0021589.t003
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Cells were cultured in 100 mm dishes (Falcon) and harvested in
lysis buffer (RIPA: PBS, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS and protease inhibitors; Santa Cruz).
After 30 min incubation on ice, lysates were cleared by
centrifugation (12000 rpm, 10 minutes). Samples containing
50 mg of total protein from lysates were separated in an SDS/
polyacrylamide gel and transferred onto a nitrocellulose mem-
brane. The rinsed and blocked membrane was then incubated
with mouse antibodies against ICAM-1 (Santa Cruz biotechnol-
ogies, Inc, Santa Cruz, CA; 1/500), goat anti-IL-1b (R&D 1/500)
or anti-GAPDH (Santa Cruz, 1/500), anti-rabbit polyclonal
antibodies against RelA, RelB, p50/NF-kB1 or p52/NF-kB2
[32] (1:1000; provided by R Weil and A Israel, Institute Pasteur,
Paris), at room temperature for 1 hour. The blot was washed and
probed with anti-mouse, -goat, or -rabbit antibodies conjugated
with horseradish peroxidase (1:10000; Dako, Glostrup, Denmark)
at room temperature for 1 hour. The blot was washed and
developed with ECL (Amersham biosciences, Orsay, France).
Patients
To investigate the in vivo inter-relationships between mRNA
levels of genes of interest, we analyzed 96 (48 ERa positive and 48
ERa negative) breast tumors excised from women at our
institution (Centre Rene ´ Huguenin, St Cloud, France). Samples
containing more than 70% of tumor cells were considered suitable
for this study. Immediately following surgery, the tumor samples
were placed in liquid nitrogen until RNA extraction. The patients
met the following criteria: primary unilateral non metastatic breast
carcinoma; complete clinical, histological and biological informa-
tion available; no radiotherapy or chemotherapy before surgery;
and full follow-up at our institution. Estrogen receptor alpha status
was determined at the protein level by biochemical method
(enzymatic immunoassay) and confirmed by ERa real-time
quantitative RT-PCR assay [33]. The malignancy of infiltrating
carcinomas was scored according to Scarff Bloom and Richard-
son’s histoprognostic system [34]. The characteristics of these
patients are shown in Table 1.
RNA extraction
RNA was isolated using TRIzol reagent according to the
manufacturer’s instructions (Invitrogen, Cergy Pontoise, France).
The quality of the RNA samples was determined by electropho-
resis through agarose gels and staining with ethidium bromide,
and the 18S and 28S RNA bands were visualized under ultraviolet
light.
Real-time quantitative-PCR
Transcript quantification of NF-kB selected genes was per-
formed as previously described [35], using the TATA box-binding
protein (TBP) as the endogenous RNA control; each sample was
normalized on the basis of its TBP content. Primers for TBP and
the 55 target genes (Table 2) were chosen with the assistance of
the Oligo 5.0 computer program (National Biosciences, Plymouth,
MN). We searched the dbEST and nr databases to confirm the
total gene specificity of the nucleotide sequences chosen as
primers, and the absence of single nucleotide polymorphisms. In
particular, the primer pairs were selected to be unique relative to
the sequences of closely related family member genes or of the
corresponding retropseudogenes. To avoid amplification of
Figure 1. Western blot analyses of IL-1b, ICAM, RelA, RelB,
NF-kB1/p50 and NF-kB2/p52 proteins in TNF-a stimulated
HMEC. HMEC cells were incubated for 4 h with 4–40 ng/ml TNF-a.
Whole cell lysates were prepared and subjected to Western blotting
using anti-ICAM, anti-IL-1b anti-RelA, anti-RelB, anti-NF-kB1/p50 or anti-
NF-kB2/p52 antibodies, as indicated in Materials and Methods.A s
loading controls, total proteins were also analyzed with anti-GAPDH.
Each lane contains 50 mg of cellular protein. Lanes 1–4 correspond to
control endothelial cells (lane 1), endothelial cells stimulated with
40 ng/ml (lanes 2 and 3) or 4 ng/ml (lane 4) TNF-a. Results were similar
in two independent experiments.
doi:10.1371/journal.pone.0021589.g001
Table 4. Dose-dependent effect of TNF-a treatment
(0–80 ng/ml) on selected NFkB gene expression in HMEC cells.
TNF-a concentration
Gene
0.2
ng/ml
1
ng/ml
2.5
ng/ml
10
ng/ml
40
ng/ml
80
ng/ml
TNF 53
a 225 559 769 1241 1210
SELE 13 65 359 609 1016 1029
VCAM 113 215 610 832 958 937
CSF2/GMCSF 140 314 443 463 714 583
IL8 179 520 691 926 1123 918
ICAM 16 63 114 123 155 139
CCL2/MCP1 16 42 53 55 70 56
CXCL1/GRO1 40 67 76 69 92 71
RELB 30 42 60 55 63 52
TNFAIP3/A20 15 26 25 32 44 32
IL1A 4 . 6 1 32 22 53 73 6
IL1B 3.2 7.8 14 14 21 17
BCL2A1 3.3 6.9 14.2 13.8 21 13
NFKB2 6.2 11.4 16 17 20 17
NFKBIA 7 . 6 1 01 21 21 91 3
CSF1 4.3 7.8 11 11 13 10
NFKB1 2.4 3.2 3.7 4.1 5.3 4.2
CD40 1.4 1.2 1.7 1.8 5.1 2.5
IL6 1.1 1.9 2.9 3.1 5.7 3.1
TNFRSF10B 2.3 3.2 3.7 3.8 5.1 3.8
aRatio of the mRNA content in cells stimulated with TNF-a for 4 h to the mRNA
content in the unstimulated cells.
doi:10.1371/journal.pone.0021589.t004
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at the junction between two exons, if possible. In general,
amplicons were between 60 and 120 nucleotides long. Gel
electrophoresis was used to verify the specificity of PCR
amplicons. For each primer pair we performed no-template
control (NTC) and no-reverse-transcriptase control (RT-negative)
assays, which produced negligible signals (usually .40 in Ct
values), suggesting that primer-dimer formation and genomic
DNA contamination effects were negligible. The cDNA synthesis
and PCR conditions have been described in detail elsewhere [35].
Results are expressed as N-fold differences in target gene
expression relative to TBP gene expression.
Statistical analysis
Statistical analysis of in vitro experiments was performed by
analysis of mean with the Student t test. The terms n=x is used to
indicate the number of independent experiments performed.
Correlations between TNF and the gene target expressions were
tested using the non parametric Spearman rank correlation test
(which compared continuous variables). Differences were judged
significant at confidence levels greater than 95% (p,0.05).
Results
Identification of TNFa-dependent NF-kB-associated
genes in microvascular endothelial cells
To determine the expression pattern of NF-kB-associated genes
in response to TNF-a in microvascular endothelial cells, we have
performed real-time RT-PCR in HMEC stimulated by TNF-a for
4 h. Our preliminary kinetic analysis on gene candidates (such as
E-selectin and IL-8) suggested an induction at 2–4 h time point
induction. Among the 55 genes tested (Table 2), only one gene,
IL12B, presented detectable but not reliably quantifiable mRNA
expression (Ct.35). Twenty (37 %) of the other 54 genes were up-
regulated by 5-fold or more (until 1200-fold) in HMEC stimulated
with TNF-a as compared to untreated cells (Table 3). These
robust selection criteria (a cut-off of 5-fold expression difference in
HMEC stimulated with TNF-a) ensure identification of genes with
marked interest.
The 20 identified genes belong to several groups according to
their biological function: adhesion molecules (SELE encoding for
E-selectin, VCAM, ICAM, and CD40), chemokines (CSF2/GMCSF,
IL8, CCL2/MCP1, CXCL1/GRO1 and CSF1), and cytokines (TNF,
IL1A, IL1B and IL6) (Table 3). Both TNFR1 and TNFR2 were
expressed at a similar level in endothelial cells, and were not
regulated by TNF-a (not shown). Interestingly, three anti-apoptotic
proteins, TNFAIP3/A20, BCL2A1 and TNFRSF10B/TRAILR2/
DR5 were markedly up-regulated. BIRC2 was moderately up-
regulated (4.4 fold), while other genes involved in apoptosis, such as
FASL, TRAF2, MCL1 and BIRC4 were not (not shown).
The expression of several components of the NF-kB signalling
cascades was also up-regulated in TNF-a stimulated HMEC, as
compared to untreated cells (Table 3). RELB (gene encoding
RelB) was strongly up-regulated (63-fold induction). In addition
NFKB2, NFKB1 and NFKBIA, which respectively encode NF-kB2
(p52/p100), NF-kB1 (p50/p105) and NF-kBIA/inhibitor IkBa
were more moderately up-regulated (10 to 20-fold). In contrast,
RELA (encoding RelA/p65), REL (encoding c-Rel) and NFKB1B
Table 5. Kinetics of selected NFkB gene expression in TNF-a treated HMEC.
Time
Gene 2 minutes 8 minutes 15 minutes 30 minutes 1 hour 4 hours 24 hours 72 hours
TNF 1.2
a 2.0 2.6 5.1 12 1241 335 2.7
SELE 0,9 1,0 1,2 1,2 1,3 1016 58 NQ
VCAM 1,0 1.1 1,2 1.8 27 958 88 6.7
CSF2/GMCSF 1.5 1.2 1.7 19 21 714 219 6.1
IL8 1.5 4.5 11 57 17 1123 331 11
ICAM 0.7 0.8 0.7 0.8 14 155 15 6.5
CCL2/MCP1 0.7 0.7 0.9 1.6 8.6 70 20 3.7
CXCL1/GRO1 1.1 3.2 6.8 11.4 4.2 92 23 2.9
RELB 1.0 1.0 1.0 1.0 25 63 30 18.5
TNFAIP3/A20 0.9 0.9 0.9 2.5 1.7 44 26 3.7
IL1A 0.6 0.6 0.6 0.7 1.0 37 7.6 0.7
IL1B 0.6 0.7 0.6 1.2 3.1 21 15 1.1
BCL2A1 1.1 1.0 1.1 1.1 3.3 21 16 0.9
NFKB2 1.6 1.0 1.6 1.4 8.8 20 12.1 5.7
NFKBIA 0.5 0.6 0.8 1.3 1.2 19 2.0 1.2
CSF1 1.0 0.8 1.0 0.9 3.5 13 5.3 2.9
NFKB1 1.0 0.9 1.1 1.0 1.7 5.0 2.8 1.5
CD40 0.6 0.4 0.6 0.7 1.6 4.7 1.7 1.8
IL6 0.7 0.9 1.0 2.6 1.7 5.4 3.3 1.9
TNFRSF10B 1.0 0.8 1.0 0.9 1.3 5.1 2.1 1.3
aRatio of the mRNA content in cells stimulated with TNF-a (40 ng/ml) for 2, 8, 15, 30 min or 1, 4, 24 and 72 h to the mRNA content in the control cell.
doi:10.1371/journal.pone.0021589.t005
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doi:10.1371/journal.pone.0021589.g002
Table 6. TNF-a up-regulates the expression of the same 20 NF-kB associated genes in HMEC and HUVEC.
HMEC cells HUVEC cells
Gene Without TNF-a With TNF-a Fold change Without TNF-a With TNF-a Fold change
TNF 14 1 1 411 11 9 8 198
SELE 17 4 3 743 23 20123 875
VCAM 11 3 1 4 1314 553 150276 272
CSF2/GMCSF 1.3 1027 790 23 3577 155
IL8 40 20172 504 24086 206710 8.6
ICAM 278 89187 321 1987 152666 77
CCL2/MCP1 1579 108418 69 3834 288180 75
CXCL1/GRO1 101 12752 126 11350 56063 4.9
RELB 145 10712 74 827 6903 8.4
TNFAIP3/A20 643 37685 59 3697 84782 23
IL1A 11 81 7.4 374 2894 7.7
IL1B 59 689 12 53 664 13
BCL2A1 12 7 27 19 733 39
NFKB2 269 6729 25 1191 8898 7.5
NFKBIA 1682 35376 21 3144 23936 7.6
CSF1 540 7385 14 2252 24483 11
NFKB1 1328 12972 9.8 2503 12581 5.0
CD40 150 944 6.3 1216 2426 2.0
IL6 49 384 7.8 290 902 3.1
TNFRSF10B 1186 6357 5.3 11253 21756 1.9
Cells were incubated in the presence of TNF-a (40 ng/ml) for 4 h. Gene expression was measured by RT-PCR, as described in Materials and Methods. For each gene,
mRNA levels were normalized such that the value for the ‘‘basal mRNA level’’ (smallest amount of target gene mRNA quantifiable, Ct=35) was 1. Ratio of the mRNA
content in stimulated cells versus unstimulated cell mRNA content was calculated. Results are expressed as the mean of two independent experiments.
doi:10.1371/journal.pone.0021589.t006
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CHUK (IkKa), IKBKB (IkKb) and IKBKG (NEMO or IkKc) were
not up-regulated (not shown).
In contrast, TNF-a did not modify the expression of a few set of
genes known to be regulated by TNFa in tumor cells (such as
MMP9). In the same set of samples, TNF-a did not modify the
expression of MKI67 gene encoding the proliferation-related Ki-
67 antigen cell proliferation marker.
To confirm that the increase of mRNA expression correlates with
induction of protein expression, cell lysates from TNF-a stimulated
HMEC were subjected to western immunoblotting using antibodies
directed against ICAM, IL-1b or several proteins of the NF-kB and
IkB families. As shown in Fig. 1, treatment of HMEC with TNF-a
strongly up-regulated the expression of IL-1b ICAM and RelB.
TNFa also increased NF-kB1/p50 and NF-kB2/p52 expression in
endothelial cells, whereas modulation of RelA protein level was not
observed, in agreement with findings at the mRNA levels.
TNF-a modulates NF-kB - associated genes in a dose- and
time-dependent manner
Expression of the NF-kB - associated genes was up-regulated with
TNF-a in a dose-dependent manner (1–80 ng/ml) in HMEC with
thesameprofile ofresponse(maximumdegreeofresponse for40 ng/
ml of TNF-a)( Table 4). Ten of these genes were up-regulated more
than 10-fold at 0.2 ng/ml, as compared to controls, with VCAM,
CSF2/GMCSF and IL8 being stimulated more than 100-fold.
We also investigated the kinetics of TNF-a-induced mRNA
expression. HMEC were treated with TNF-a (40 ng/ml) at
different time periods (0 to 72 h). We observed the same profile
of response for all genes, with a maximum induction always
observed at 4 hours of TNF-a treatment (Table 5), associated to a
marked decreased at 24 and 72 hours.
Quantitative and qualitative differences in the expression
of the NF-kB-associated genes between microvascular
and macrovascular endothelial cells
Quantitative RT-PCR was used to compare the expression of
NF-kB associated genes in TNF-a stimulated HUVEC and
HMEC (40 ng/ml for 4 h). As shown in Table 6, TNF-a up-
regulated the expression of the same 20 NF-kB associated genes on
the two classes of endothelial cells, except for CD40, IL6 and
TNFRSF10B that are hardly induced in HUVEC. Interestingly, for
VCAM, ICAM, IL8, CSF2, CXCL1/GRO1, RELB, IL6 and
TNFRSF10B expression, the fold induction was much higher in
HMEC, as compared to HUVEC. However, these results were
probably due to a lower basal expression level in HMEC
compared to HUVEC (Table 6). Fig. 2 shows the mRNA levels
of three characteristic genes (CCL2/MCP1, IL8 and IL1A) in TNF-
a-stimulated HUVEC and HMEC cells. Finally, it is interesting to
note that among the 35 genes whose expression was not up-
regulated (.5-fold) in stimulated HMEC, no gene was up-
regulated in HUVEC (.5-fold) (not shown).
Table 7. Inhibitory effect of SiRNA TNFR on TNF-a-induced genes in HMEC endothelial cells.
Gene
Control SiRNA
+TNF-a
SiRNA
TNFR1 + TNF-a
% inhibition
via R1
Control SiRNA
+TNF-a
SiRNA
TNFR2 + TNF-a % inhibition via R2
TNF R1 1.7 0.94 45 0.95 0.89 7
TNFR2 1.41 1.56 0 10.3 2.43 77
TNF .225 .158 30 185.5 155 17
SELE .19 .9 ND .65 .51 ND
VCAM 124 75.6 40 .153 .218 ND
CSF2/GMCSF 92 52.5 43 97 70 28
IL8 86 43.5 50 59.3 62 0
ICAM 288 171.8 40 113 101.5 11
CCL2/MCP1 162.7 122.3 25 61.8 59.4 4
CXCL1/GRO1 21.7 17 22 18.6 19 0
RELB 17.3 14.5 16 6.47 6.49 0
TNFAIP3/A20 12.6 8.4 33 10.1 10.7 0
IL1A 11.7 5 57 18.8 17.8 6
IL1B 81.4 39.7 51 25.5 19 26
BCL2A1 10.5 5.5 48 10 12 0
NFKB2 10.6 7.6 28 4.8 5 0
NFKBIA 85 . 8 27 4.43 4.78 0
CSF1 15.7 10.9 30 7.7 7.9 0
NFKB1 6.4 4.5 30 3.5 3.5 0
CD40 3.3 2.5 23 3.3 3.1 5
IL6 8.7 5.2 40 5.13 5.43 0
TNFRSF10B 3.7 2.7 26 3.56 2.8 22
aResults are expressed as ratio (in percentage) of the mRNA content in siRNA TNFR-transfected cells stimulated with TNF-a (40 ng/ml) for 4 h to the mRNA content in
unstimulated cells. After transfection with siTNFR1 or siTNFR2 RNAs, TNFR1 and TNFR2 expression were strongly inhibited (45 % and 77 %, respectively). Results are
expressed as the mean of two different independent experiments.
doi:10.1371/journal.pone.0021589.t007
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NF-kB -- associated genes
We then analysed the mechanisms of the regulation by TNF-a
observed in endothelial cells first using silencing of TNF receptors.
SinceTNFR1(orTNF-Rp55)andTNFR2(orTNF-Rp75)areboth
present in endothelial cells, we silenced the expression of each
receptorbyRNAinterferenceinHMEC.Inthe presenceofTNF-a,
the expression of TNFR1 was reduced from 45 % in siRNA
TNFR1-transfected cells, as compared to siRNA control (Table 7).
In these cells, the expression of twelve NF-kB associated genes
including VCAM, ICAM, CSF2/GMCSF and CSF1, the cytokines
TNF, IL8, IL1A, IL1B and IL6, TNFAIP3, BCL2A1 and NFKB1 was
inhibited more than 30 %, as compared to TNF-a stimulated
siRNA control-transfected cells (Table 7). In contrast, TNFR2
expression was not reduced in siRNA TNFR1-transfected cells,
suggesting that the decrease of TNFR1 expression was receptor
specific. We further tested the putative involvement of TNFR2 in
TNF-a response in endothelial cells. The expression of TNFR2, but
not TNFR1, was reduced from 77 % in HMEC transfected with
siRNA TNFR2. Only 4 genes including CSF2/GMCSF, IL1B,
TNFRSF10B and TNF were inhibited more than 15 % (28 %, 26 %,
22 % and 17 %, respectively) when TNFR2 was silenced (Table 7).
Altogether,theseresults indicatethatTNFR1and,toa lesserextent,
TNFR2 are involved in the control of the NF-kB associated gene
signature in TNF-a stimulated endothelial cells.
NF-kB activation is involved in TNF-a-induced gene
expression in endothelial cells
We next examined the effects of chemical inhibition of IkB
phosphorylation and IkappaB kinase activity on gene expression
in TNF-stimulated HMEC (Table 8). Bay 11–7082, an inhibitor
IkB phosphorylation [27] was first tested on NF-kB activity in
endothelial cells using a luciferase reporter gene whose activity
depends on a kB element. Luciferase activity was decreased by 99
% after addition of Bay 11–7082 (10 mM) on TNF-a treated
endothelial cells (data not shown). Most importantly, the addition of
Bay 11–7082 resulted in decreased expression of all selected
genes in TNF-a treated HMEC (Table 8). As a control, TNFR
receptor expression which was not changed by TNF-a stimula-
tion was insensitive to Bay 11–7082. The addition of pharma-
cological IkB kinase (IKK2) inhibitor V [28] also inhibited the
expression of VCAM, ICAM, CCL2/MCP1 and BCL2A1 and
IL1Bat 1–10 mM( Table 8); surprisingly, it activated CSF2/
GMCSF, TNFAIP3, IL1A and IL8. Altogether these experiments
using two different inhibitors suggest that canonical NF-kB
signalling pathway is involved in TNF-k-induced gene expression
in endothelial cells.
To directly demonstrate the involvement of NF-kBi nt h eg e n e
signature induced by TNF-a in endothelial cells, we first evaluated
TNFa-induced activation of NF-kB complexes in HMEC cells by
EMSA. As shown in Fig 3A,T N F - a treatment in HMEC resulted in
Figure 3. RelA knock-down by RNAi blocks TNFa-induced gene
expression in HMEC cells. (A) Nuclear extracts from HMEC cells
treated with TNF-a for the indicated periods of time were analyzed by
EMSA using a
32P-labeled HIV-LTR tandem kB oligonucleotide as a probe.
(B) For supershift, nuclear extracts from HMEC cells treated with TNFa for
4 hours were incubated with the indicated antibodies before incubation
with the labeled probe. Complex I: RelA/p50. (C) Nuclear extracts from
HMEC cells stably transduced with a lentivirus encoding a shRNA
targeting either RelA or a scrambled control, and treated by TNFa for the
indicated periods of time were analyzed by EMSA as described in (A).
doi:10.1371/journal.pone.0021589.g003
Table 8. Inhibitory effects of Bay 11–7082 and IKK2 inhibitor
V on TNF-a-induced genes in HMEC endothelial cells.
Gene TNF-a
TNF-a + Bay
11-7082 TNF-a
IKK2+TNF-a
1 mM
IKK2+TNF-
a10 mM
TNF R1 0.6 0.8 0.86 0.8 1
TNFR2 0.8 2.4 1.8 1.1 1
TNF 78 NE 34 19 22
SELE 9.5 1.6 4 4 3.7
VCAM 47.5 NE 24.8 24.9 7.3
CSF2/GMCSF 22.8 0.4 136 286 337
IL8 157 2.2 246 419 368
ICAM 332 1.1 450 284 261
CCL2/MCP1 85 0.9 162 114 42.3
CXCL1/GRO1 20 1 33.4 39.5 29.2
RELB 12.4 0.5 28 26.8 22.7
TNFAIP3/A20 11 2.4 17.6 26.6 29.6
IL1A 20.3 0.9 23.4 30.4 57
IL1B 15.6 1.5 29.8 25.6 16.3
BCL2A1 2.6 0.3 9 4.6 3.6
NFKB2 7.5 1 12.7 10.1 10
NFKBIA 5.5 0.6 6.3 6.8 7.7
CSF1 14.9 1.1 16.5 14.7 16.2
NFKB1 4.4 0.8 6 6 5.3
CD40 2.6 1.6 2.1 1.7 1.8
IL6 8 1.2 10.7 10.7 13.4
TNFRSF10B 3 2.2 4.3 3.6 4.4
Cells were pre-treated with pharmacological inhibitors of NF-kB, Bay 11–7082
10 mM or IKK2 inhibitor V (1 and 10 mM), for 30 min before incubation with
40 ng/ml TNF-a for 4 h. mRNA levels were normalized to unstimulated cells
which values were set to 1.
doi:10.1371/journal.pone.0021589.t008
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Supershift analysis of nuclear extracts stimulated for 4 h with TNF-a
indicated that the NF-kB DNA-binding complexes consist of RelA-
p50 dimers (Fig 3B).
We then used stable RNA interference knock-down to inhibit
RelA activity inHMEC cells.We infected HMEC cells with either a
lentivirus carrying a shRNA targeting RelA or a scrambled control.
Whereas TNFa stimulation of scrambled control-infected HMEC
cells induced RelA DNA binding with kinetics that parallel what is
seen in non-infected cells, RelA expression knock-down almost
completely abolished RelA-DNA binding activity (Fig 3C).
We then examined the mRNA expression levels of 16 genes
by real time RT-PCR. The down-regulation of RelA activity
clearly inhibited the expression of all of them except
TNFRSF10B (Table 9), thus indicating that RelA is required
for the TNF-a-induced expression of these genes in HMEC
cells.
Positive correlation between the expression of
TNF-a mRNA and of the 19 other identified putative
TNF-inducible genes in 96 human breast tumors
TNF-a is highly expressed in tumors where it has been
considered initially as a potent tumor cell killer and an anti-
vascular cytokine at high doses [36]. However, low chronic doses
of the cytokine are thought to be pro-angiogenic [4]. In order to
test the involvement of TNF-a activation/endothelial dysfunc-
tion of the breast tumor vasculature, we further explored if the
correlations identified in our ex vivo cellular model (endothelial
cells) between the expression of TNF-a mRNA and the
expression of 19 putative TNF-a-i n d u c i b l eN F - kBt a r g e tg e n e s
were also observed ex vivo in human breast tumors.
This study was performed on a series of 96 breast tumors (48
ERa-positive and 48 ERa-negative tumors) (Table 1). We
observed a positive correlation between TNF and 16 (84.2 %) of
the 19 endothelial TNF-a-inducible genes in both ERa-negative
and ERa-positive breast tumors (Table 10). The three remaining
genes (i.e., IL8, IL1A and IL6) were significantly linked to TNF
only in ERa-negative tumors. In the same set of 96 tumors, we
also examined the expression of the ESR1 gene, which encodes
ERa as well as the proliferation-associated gene MKI67,w h i c h
encodes the proliferation-related antigen Ki-67. We found no
correlation between TNF and ESR1 and MKI67, suggesting that
the 19 genes were associated to TNF independently to hormonal
status and cell proliferation.
Prognostic value of TNF-a mRNA and of the 19 putative
TNF-inducible gene mRNAs in human breast tumors
We estimated the prognostic value of the TNF-a mRNA and the
19 other identified putative TNF-a-inducible gene mRNAs in our
series of 96 breast tumors (48 ERa-positive and 48 ERa-negative
tumors). In the cohort of 48 ERa-negative breast tumors, nineteen
patients relapsed, whereas in the cohort of 48 ERa-positive breast
tumors, twenty-seven patients relapsed (Table 11). We used
univariate analysis (log-rank test) to study the prognostic value of
these 20 genes. For each gene, the 48 ERa-positive (or –negative)
breast tumors were divided into two equal groups of 24 tumors
Table 10. Relationship between expression of TNF and
expression of the 19 others identified putative TNF-inducible
genes in 48 REa negative breast tumors and 48 REa positive
breast tumors.
Gene TNF mRNA level
REa negative breast tumors REa positive breast tumors
SELE 0,731
a ,0,0000001
b 0,387
a 0,0065
b
VCAM 0,690 0,0000002 0,403 0,0045
CSF2/GMCSF 0,589 0,00002 0,373 0,0089
IL8 0,333 0,02 0,202 NS (0,17)
ICAM 0,846 ,0,0000001 0,577 0,000031
CCL2/MCP1 0,640 0,000002 0,578 0,000029
CXCL1/GRO1 0,494 0,0004 0,300 0,036
RELB 0,858 ,0,0000001 0,619 0,000006
TNFAIP3/A20 0,815 ,0,0000001 0,593 0,000024
IL1A 0,489 0,0005 0,248 NS (0,086)
IL1B 0,772 ,0,0000001 0,477 0,0007
BCL2A1 0,760 ,0,0000001 0,434 0,0022
NFKB2 0,826 ,0,0000001 0,570 0,000038
NFKB1A 0,705 ,0,0000001 0,592 0,000018
CSF1 0,851 ,0,0000001 0,427 0,0026
NFKB1 0,691 0,0000002 0,292 0,041
CD40 0,792 ,0,0000001 0,433 0,0022
IL6 0,307 0,03 0,275 NS (0.056)
TNFRSF10B 0,655 0,000001 0,346 0,015
MKI67 0,079 NS (0,60) 20,036 NS (0.83)
ESR1 - - 20,063 NS (0.63)
aSpearman correlation coefficient.
bP value, Spearman rank correlation test.
NS, not significant.
doi:10.1371/journal.pone.0021589.t010
Table 9. Effect of ShRNA RelA on TNF-a-induced genes in
HMEC endothelial cells.
Gene
Control ShRNALuc
+TNF-a
ShRNA RelA +
TNF-a % inhibition
CCL2 8.4 2.1 74.8
CD40 1.6 1 41.4
CSF1 3.2 2.2 31.9
CSF2 79.7 40.8 48.8
CXCL1 18.6 3.45 81.4
ICAM 17.7 2.1 85.8
IL1A 55.8 12.3 77.9
IL1B 44 4.1 90.5
IL6 17 0 100
IL8 135.9 10.4 92.3
NFKB1 31 . 2 60.5
NFKB2 11.5 6.2 46
NFKBIA 22.3 3.1 85.8
RelB 5.4 1.4 74.6
TNFAIP3 30 6.8 77.1
TNFRSF10B 2.4 2.4 0
For each gene and each sample, mRNA levels were normalized such that the
value of the Control shRNALuc sample was 1.The inhibition by ShRNA RelA is
expressed as pourcentage of the difference between control shRNA Luc vs
shRNA RelA in cells stimulated with TNF-a (40 ng/ml) for 4 h. Genes were
classified by alphabetical order.
doi:10.1371/journal.pone.0021589.t009
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that only low expression level of NFKB2 in the cohort of 48 ERa-
negative breast tumors and high expression level of IL8 in the
cohort of 48 ERa-positive breast tumors correlated with
significantly shorter metastases-free survival, but at the limit of
the significance (p=0.039 and p=0.022, respectively) (Table 11).
Discussion
This study documents, for the first time, the NF-kB gene
expression signature in two different subtypes of TNFa-stimulated
endothelial cells, especially in HMEC which originate from the
microcirculation and have been much less studied as compared to
HUVEC. Twenty genes were up-regulated 5-fold or more (until
1200-fold) in TNFa-stimulated endothelial cells, in a concentra-
tion- and time-dependent manner. The up-regulated genes include
those controlling cytokines, chemokines and adhesion molecules,
relevant to inflammation and apoptosis, as well as factors involved
in the immune system. The most highly up-regulated genes in
TNFa-stimulated endothelial cells are those encoding adhesion
molecules and cytokines/chemokines (i.e., TNF-a, IL-8, MCP-1
and GM-CSF/CSF2). Novel observations concern the up-
regulation of TNFAIP3, CXCL1/Gro1, GM-CSF/CSF2 and MCF/
CSF1, TNFRSF10B/Trail R2 (DR5), CD40 and TNF itself in
TNFa-stimulated endothelial cells via NF-kB, as well as selective
expression of NF-kB components (RELB, NFKB1 and NFKB2).
Interestingly, while TNFR1 was involved in all the regulations
observed, some of the regulated genes were shown to be regulated
through both TNFR1 and TNFR2. Moreover, the correlations
identified in our ex vivo cellular model (endothelial cells) between
the expression of TNF-a mRNA and the expression of 19 putative
TNF-a- inducible NF-kB target genes were also observed in
human breast tumors.
The up-regulation of adhesion molecules (VCAM-1, ICAM-1
and E-selectin) and pro-inflammatory cytokines (IL1a,I L b and
IL-6) in TNFa-stimulated endothelial cells through NF-kB agrees
with previous findings reported in HUVEC [16-18].IL-6 expression
was poorly modulated by NF-kB activation in these cells.
Interestingly, our results show that TNF-a strongly up-regulates
TNF-a itself (but not TNFR1 and TNFR2 expression), as well as the
expression of DR5 (TNFRSF10B or TRAIL-R2) and CD40, two
additional members of the TNF/TNF receptor superfamily
involved in the immune system [3]. Such induction occurs through
TNFR1 and TNFR2 and via NF-kB activation. Interestingly, DR5
has been detected in endothelial cells derived from blood brain
barrier (HBEC), where it released MMP9 upon activation [37].
The chemokines IL-8/CXCL8, CXCL1/Gro1, CCL2/MCP-1,
GMCSF/CSF2 and MCF/CSF1 were significantly up-regulated
more than 5 fold in HMEC and HUVEC. Their expression was up-
regulated as early as 30 min-1 h and sustained for up to 24 h, as
previously described for IL-8 and CCL2/MCP-1 in HUVEC
[15,38]. The up-regulation of IL-8 through NF-kB has not been
described before in TNF-a-induced endothelial cells. IL-8, CCL2/
MCP-1 and CXCL1/Gro1 facilitate the subset specific recruitment
of neutrophils, monocytes, T lymphocytes or NK cells. In addition
to their chemotactic activity, the three chemokines possess
angiogenic activity in vitro [39] and are involved in the regulation
of tumoral angiogenesis such as in breast cancer [40-41]. Our study
further shows for the first time that GM-CSF/CSF2 and MCF/
CSF1 expression is induced through NF-kB in HMEC. CSF1 has
been previously shown to be induced in HUVEC by endotoxin [42-
43]. This chemokine promotes differentiation of hematopoietic cells
to mature granulocytes and macrophages. GM-CSF/CSF2 is
involved in the recruitment of macrophages in various inflamma-
tory diseases and was recently found to mobilize bone marrow
progenitors [44]. This chemokine is also involved in angiogenesis
and is a key target of NF-kB in cancer and metastasis [45].
Bcl2A1 (A1) and TNFAIP3 (also known as A20) are anti-
apoptotic proteins expressed in endothelial cells [46-48], and have
also been associated with angiogenesis [49]. Their expression was
shown to be up-regulated by TNF-a in both HUVEC and
HMEC, in contrast to other classical NF-kB-inducible anti-
apoptotic proteins, such as MCL1S, MCL1L, BIRC2 (c-IAP1),
BIRC4 (XIAP) and TRAF2. To our knowledge, our study
indicates for the first time the up-regulation of TNFAIP3/A20
gene expression by TNF-a through NF-kB.
In our study, several approaches were used to demonstrate the
involvement of the NF-kB canonical activation pathway in TNF-
a-induced gene expression in endothelial cells. Our observations
showing that genes encoding the kinases IkKa (CHUK), IkKb
(IKBKB) and NEMO/IkKc (IKBKG) were not up-regulated by
TNF-a in endothelial cells indicate that changes in the NF-kB
target gene expression is not dependent upon changes in the
expression of these kinases. The decreased expression of the NF-
kB-mediated genes in TNF-a treated HMEC in the presence of
Bay11–7082 (a specific inhibitor of cytokine-induced IkBa
phosphorylation), is in agreement with the involvement of this
Table 11. Statistical analysis of mRNA expression of genes in
96 breast tumors relative to relapse.
P-value
a
REa negative breast tumors REa positive breast tumors
Metastases
Yes 19 27
No 29 21
Genes
TNF 0.60 (NS) 0.59 (NS)
SELE 0.83 (NS) 0.99 (NS)
VCAM 0.92 (NS) 0.78 (NS)
CSF2/GMCSF 0.11 (NS) 0.099 (NS)
IL8 0.72 (NS) 0.022
ICAM 0.38 (NS) 0.098 (NS)
CCL2/MCP1 0.99 (NS) 0.13 (NS)
CXCL1/GRO1 0.90 (NS) 0.33 (NS)
RELB 0.89 (NS) 0.45 (NS)
TNFAIP3/A20 0.62 (NS) 0.49 (NS)
IL1A 0.62 (NS) 0.27 (NS)
IL1B 0.51 (NS) 0.55 (NS)
BCL2A1 0.25 (NS) 0.78 (NS)
NFKB2 0.039 0.34 (NS)
NFKBIA 0.94 (NS) 0.61 (NS)
CSF1 0.43 (NS) 0.70 (NS)
NFKB1 0.65 (NS) 0.84 (NS)
CD40 0.41 (NS) 0.53 (NS)
IL6 0.65 (NS) 0.78 (NS)
TNFRSF10B 0.21 (NS) 0.66 (NS)
MKI67 0.26 (NS) 0.56 (NS)
ESR1 - 0.059 (NS)
aLog-rank Test.
doi:10.1371/journal.pone.0021589.t011
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showing the time-dependent phosphorylation of IkBa and nuclear
translocation of p50 (NF-kB1) in TNF-a endothelial cells
(L Michel and M Applanat, not shown). The most direct
demonstration that TNF-a-induced gene expression in HMEC
depends on NF-kB activation arises from RelA knock-down
experiments, RelA representing the major NF-kB activity in
HMEC stimulated by TNFa [50] (see Fig. 3). Nonetheless, the
expression of TNFRSF10B is not significantly down-regulated by
RelA knock-down as compared to the effect observed with the
chemical inhibitors.
The significance of the selective increase of expression of RELB,
NFKB1 and NFKB2/p52, Rel/NF-kB family members, but not
RelA and c-rel, which is demonstrated for the first time in TNFa-
stimulated endothelial cells, is unknown. These up-regulations
occur at both the mRNA and protein levels, and correlate with
nuclear translocation of p52 (not shown). These findings suggest that
heterodimers NF-kB2 (p52)/RelA or p52/p52 could also favour
TNF-a signalling in endothelial cells. Of note, TNFRSF10B/DR5
has previously been shown to be activated by p52 in some context
[51]. The non canonical pathway is known to be activated by
stimuli such as lymphotoxin-b, CD40L and BAFF, involves IKKa
(IKK1) activation and nuclear translocation of RelB in the form of
RelB/p52 and RelB/p50 dimers [9–10,11,51–52].
Our study also contributes to analyze the role of TNFR1 and
TNFR2 receptors, which are expressed at a similar level in
endothelial cells. The decrease of gene expression is observed in
TNFa-stimulated endothelial cells after silencing TNFR1; this
receptor is thought to mediate the majority of the biological effects
of the TNFa and the classical pathway of TNF-a signalling.
However, silencing of TNFR2 also decreases the expression of
IL1B, GM-CSF/CSF2, TNFRSF10B/Trail R2 and TNF, suggesting
that both TNFR1 and TNFR2 are involved in TNF-a dependent
up-regulation of these genes in HMEC.
TNF-a and its related NF-kB transcription factor are described
as critical components of tumor progression [20,22]. NF-kBi s
deregulated in breast cancer patients and in breast cancer cells
[25,53–55]. Several studies have shown that tumor-associated
neovascularisation is a prerequisite of rapid growth and metastasis
[56]. Although great strides have been made in the elucidation of
molecular mechanisms of tumor vasculature, different markers
and many essential interactions have to be yet determined. Among
genes described in this study, IL8, CCL2/MCP1, CXCL1/Gro1,
Bcl2 and TNFAIP3 are known to be pro-angiogenic [38–
40,49,57]. Moreover, one of the consequences for TNF-a ´
activation of tumor endothelial cells is also to recruit numerous
cells through chemokines and adhesion molecules, including
monocytes, neutrophils, fibroblasts and immune cells inside the
tumor.
Our study provides for the first time a significant correlation
between TNF-a expression and the expression of putative TNF-a-
inducible NF-kB target genes (as identified in microvascular
endothelial cells) in human breast tumors (Table 10). The highest
correlation between TNF-a and NF-kB related genes was
observed for ERalpha negative-, as compared to ERpositive-
breast tumors. TNF-a expression and IL8, IL1A and IL6
expression were only correlated in ER-negative, but not in ER-
positive breast tumors. A distinct pattern of activation of NF-kB
subunits (c-Rel, RelB, p50/ NF-kB1, p52/ NF-kB2, and Ik-Ba), as
well as the absence (or low level) of nuclear p65/RelA has also
been previously described in breast tumors, as compared to
normal adjacent tissue [22,48]. Altogether, these data suggest that
dysregulated/TNF-a stimulated endothelial cells through NF-kB
are likely to play an important role in breast cancer.
In conclusion, we describe for the first time the profile of
cytokines, chemokines, adhesion molecules and NF-kB compo-
nents induced in endothelial cells stimulated by TNF-a through
TNFR and NF-kB. This study provides a NF-kB gene signature
associated with TNF-a stimulation in endothelial cells. Some of
the newly identified regulated genes, such as those involved in the
recruitment of bone marrow or endothelial cell progenitors, will be
further explored in a mouse cancer model. The cytokines,
chemokines, adhesion molecules and angiogenic factors, as well
as factors involved in the immune system, that we have identified
in TNF-a stimulated endothelial cells may also promote tumor
progression in vivo.
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